System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Eric Lambaudie is an expert in Oncology at Institut Paoli-Calmettes (France). As of July 2026, ScienceLeadR ranks Eric Lambaudie in the top 1% of experts worldwide for Genital Neoplasms, Female. Eric Lambaudie has authored 294 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 2 of them ongoing. SLR score: 882 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Eric Lambaudie Institut Paoli-Calmettes France
882 ScienceLeadR Reputation 882

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gynecology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Institute Paoli-Calmettes

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 294

Citations

Citations: 4 884 1st author: 26 Last author: 56 Unique author: 0

Main journals

Int J Gynecol Cancer 24
Gynecol Obstet Fertil 18
Bull Cancer 15
Eur J Obstet Gynecol Reprod Biol 15
Cancer Res 14

Best Journals

J Clin Oncol 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy of secondary cytoreductive surgery for relapsed ovarian low-grade serous carcinoma: a multicenter analysis from French TMRG network.
PMID 42411723 — cytoreduction surgical procedures, ovary, neoplasms, ovarian neoplasms		J Gynecol Oncol20260
[Robotic surgery in oncologic procedures: Overview of platforms currently available in France and practical comparison criteria].
PMID 42309834 — neoplasms		Bull Cancer20260
Could systematic ileostomy decrease anastomotic leakage after modified posterior exenteration in advanced stage ovarian cancer patients? retrospective cohort analysis of two referral centers.
PMID 42061050 — reproduction, ovary, neoplasms, obstetrics, ovarian neoplasms, multivariate analysis, gynecology, peritoneal neoplasms, anastomotic leak, ileostomy		Eur J Obstet Gynecol Reprod Biol20260
Advanced high-grade serous ovarian cancer treated with intensive cytoreductive surgery and chemotherapy: prognostic impact of lymph node involvement: analysis of the French national ESME-Unicancer database.
PMID 42013623 — cytoreduction surgical procedures, lymph nodes, ovary, neoplasms, drug therapy, lymph, ovarian neoplasms, therapeutics, dissection, prognosis, chemotherapy		Eur J Surg Oncol20260
Impact of practising an adapted and collective physical activity, such as five-a-side touch rugby, on the physical self-esteem of patients treated or followed up for breast or gynaecological cancer.
PMID 41296092 — exercise, touch, neoplasms, breast, palliative care		Support Care Cancer20250

Clinical Studies 13

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Director: 1

By phase:

N/A 11
Phase 3 2

By status:

Active not recruiting 4
Completed 4
Unknown 2
Not yet recruiting 1
Recruiting 1
Terminated 1

By type:

Interventional 10
Observational 3

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 0
multicentricup10 5

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
PARa aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
NCT05581121 — radiotherapy, carcinoma, adenosquamous, lymph nodes, lymph node excision, uterine cervical neoplasms, brachytherapy, neoplasms, adenocarcinoma, laparoscopy, human papillomavirus 16, lymph, therapeutics, carcinoma		Phase 3Recruiting2023
Connected Prehabilitation Program During Neo Adjuvant Chemotherapy
NCT04451369 — physical fitness, ovary, neoplasms, drug therapy, chemotherapy, adjuvant, ovarian neoplasms, therapeutics, carcinoma, ovarian epithelial, chemotherapy, carcinoma		N/ANot yet recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS